|
|
|
|
 |
Scott C.
Gottlieb
Injury Law Attorney
29 Riverside Drive
Binghamton, NY 13905
Phone: 607-724-7700
Fax: 607-724-5370 |
|
|
 |
|
|
| |
|
 |
|
Glossary of Prescription Drug Terms
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P Q
R
S
T U
V
W X Y
Z #
Click on the first letter of the word from the list above to
go to the appropriate section of the glossary. Contact us if you would like a
personal injury law glossary or one of other legal glossaries for your website.
Legal Glossaries Main Page
-
Z -
Zyban: According to the Telegraph, Doctors in
Great Britain monitoring the safety of Zyban, an
anti-smoking drug, have reported the deaths of 18
patients who had been prescribed the medicine. Since
it became available on a prescription basis last
June, 270,000 smokers in Britain have been given
courses of the drug, which works by inhibiting the
craving for cigarettes. The Telegraph reports that
the British version of the FDA, the Medicines
Control Agency, which is conducting an intensive
monitoring program on Zyban, has received reports of
3,457 patients complaining of adverse reactions.
There have been 73 reports of people suffering
seizures. One of those was a Manchester ambulance
driver who crashed when responding to an emergency
call. A Department of Health spokesman said: "We
have asked GPs to report all suspected adverse
reactions. The drug has been widely prescribed so we
were expecting a large number of reports. Australian
Health authorities are investigating the deaths of
nine Australians to establish whether their use of
the controversial anti-smoking drug Zyban was a
contributing factor. Canadian officials are also
investigating the safety of Zyban, according to
Health Canada data dating back to September 1999.
There have been 407 adverse events related to Zyban,
of which include three reported deaths. In the
United States, Zyban has been prescribed to more
than 5 million smokers since it was approved by the
FDA, as a prescription anti-smoking drug in 1997.
Previously, it was available as an antidepressant
under the brand name Wellbutrin. In a New York Post
story in May 2001, Dr. Jerome Giron, pulmonary
specialist at the NYU Downtown hospital believes the
deaths overseas should not be ignored. Giron has
prescribed Zyban to about 100 patients, and only
around a third has stuck with the drug for the full
eight-week course. "I've found it's not very well
tolerated. People have said that they feel "spaced
out" and "jittery" like they were going out of their
minds. There've been a lot of problems with
nervousness."
Zyprexa: Zyprexa is an anti-psychotic medication
made by Eli Lilly & Co., and approved in 1996 by the
U.S. Food and Drug Administration for the treatment
of schizophrenia and bipolar mania. Zyprexa is a
member of a class of drugs known as “second
generation anti-psychotics” (SGAs) or “atypical
anti-psychotics”. Of the six SGAs currently
available on the market, Zyprexa, generic name
olanzapine, is the most commonly prescribed drug. On
June 9, 2005, Eli Lilly & Co. announced that it will
pay nearly $700 million to settle about
three-quarters of the current liability cases. These
cases claim that labels on Zyprexa failed to provide
adequate warning that the drug could put patients
more at risk for developing diabetes. Most of the
nearly 8,000 lawsuits claim that before September
2003, the information on Zyprexa labels did not
adequately warn patients that taking the drug might
put them at risk of developing hyperglycemia and
diabetes. In September 2003, the FDA ordered Eli
Lilly & Co. to revise the labeling and product
information. Among the more serious outcomes
resulting from hyperglycemic abnormalities are
diabetic ketoacidosis, diabetic coma and, in some
cases, death. In February 2004, Eli Lilly & Co.
notified doctors and psychiatrists that elderly
patients with dementia face an increased risk of
stroke with Zyprexa treatment. While not approved
for use in elderly dementia patients, or for anxiety
or depression, physicians still prescribed the drug
on an “off-label” basis. Off-label use refers to the
practice of marketing or prescribing a drug in a
different dose, for a longer period of time, or for
a different medical condition than approved by the
FDA. Other health risks associated with Zyprexa and
other antipsychotic medications include:
- A life-threatening nervous system problem called neuroleptic malignant syndrome (NMS). NMS can cause
a high fever, stiff muscles, sweating, a fast or
irregular heart beat, change in blood pressure, and
confusion. NMS is considered a medical emergency.
- A movement problem called tardive dyskinesia.
High blood sugar and diabetes.
- Strokes have happened in older patients treated
for mental illness from dementia. Zyprexa is not
approved for this use.
|
|
|
VIDEO CENTER
You do not have the Flash plugin installed, or your browser does not support Javascript. Please
install it to view our movies.
To hear more from Attorney Gottlieb, please choose a video below.
|
 |
CONTACT A LAWYER |
|
|
 |
|
| |
|